CANTON, Mass. and LAS VEGAS, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that the latest advanced wound care research on Apligraf® and NuShield® will be presented at the Symposium on Advanced Wound Care (SAWC) Fall 2019 meeting, held Oct. 12-14 in Las Vegas.
Visitors to the Organogenesis exhibition booth (#301) and presentation attendees will have the opportunity to learn about the Company’s product portfolio and its latest advances in wound care.
Organogenesis will sponsor a lunch symposium titled “Get Wounds Moving with a Comprehensive Portfolio of Skin Substitutes” on Saturday, October 12 from 11:40 a.m. – 1:10 p.m. The symposium will be led by Andrew Rader, DPM, FAENS, FACFAOM, FAPWCA, FACCWS.
A CME Breakfast Symposium, supported by an Organogenesis educational grant, will also take place Sunday, October 13 from 7:30 – 9 a.m. The symposium will feature a presentation by George Koullias, MD, and Andrew Rader, DPM, titled “Do Processing and Layers Matter? The Science and Clinical Experience of a Complete Dehydrated Placental Derived Modality.”
“The Symposium on Advanced Wound Care provides an excellent forum to connect wound care experts and improve patient outcomes through education,” said Shabnam Vaezzadeh, MD, MPA, Vice President of Global Medical and Clinical Affairs for Organogenesis. “We are excited about the opportunity to engage with leaders of this community, to showcase Organogenesis products and clinical programs, and to continue to advance the science and practice of wound healing.”
POSTER PRESENTATIONS OF INTEREST INCLUDE:
Characterization and Preclinical Evaluation of Dehydrated Human Amnion Chorion Grafts
John P McQuilling, Miranda Burnette, Kelly Kimmerling, MaryRose Kammer, Katie C Mowry
Value Based Healthcare: Using Bilayered Living Cellular Construct for Treatment of Venous Leg Ulcers
Aseel Bin Sawad, George J Koullias
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts for future events. Forward-looking statements may be identified by the use of words such as “will,” “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” “extend,” “continue” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including Item 1A (Risk Factors) of the Company’s Form 10-K for the year ended December 31, 2018. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit www.organogenesis.com.
Press and Media Inquiries:
Mike Piccinino, CFA